- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07947420
Effect of Low Intensity Pulsed Ultrasound on Involution of the Uterus Postpartum
The aim of this study is to determine the effect of low intensity pulsed ultrasound on subinvolution of the uterus postpartum.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Low intensity pulsed ultrasound (LIPUS) is a safe and effective treatment for uterine involution. It contributes to uterine contraction after cesarean section, shortens the duration of lochia and relieves postpartum pain, thus decreasing the incidence of poor uterine involution, reducing vaginal bleeding and decreasing fundal height which was assessed using fundal level test. LIPUS can increase the frequency and amplitude of spontaneous contractions of the uterus in postpartum women. Therefore, this study will be conducted to investigate the effect of LIPUS on subinvolution through decreasing the incidence of delayed uterine atony and postpartum hemorrhage in postpartum women whether they had vaginal or cesarean delivery. There is no previous study illustrating the effect of LIPUS on subinvolution by using an objective measurement, so in this study, the effect of LIPUS will be measured using an evaluative ultrasonography. This study will add a new piece of information that maybe helpful for women suffering from this condition and may help the field of physical therapy for women health.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Mahitab M Yosri, PHD
- Phone Number: 01222606996
- Email: mahitab.yosri@pt.cu.edu.eg
Study Contact Backup
- Name: Alaa H Ibrahim, Bachelor
- Phone Number: 01019209456
- Email: alaahisham197@gmail.com
Study Locations
-
-
-
Tanta, Egypt
- Cairo university
-
Contact:
- Alaa H Ibrahim, Bachlor
- Phone Number: 01019209456
- Email: alaahisham197@gmail.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Postpartum women with uterine subinvolution (delivered vaginally or through caesarean section).
- All women are regularly lactating.
- Their age will be ranged from 25 to 40 years old.
- Their body mass index will be ranged from 20 - 30 kg/m².
Exclusion Criteria:
- History of abdominal surgeries except for cesarean section.
- Abdominal skin diseases, lesions, injuries, burns or open wounds.
- Any malignant tumors or fibroids.
- Coagulation disorders.
- History of chronic diseases such as diabetes, hypertension, cardiovascular and pulmonary diseases.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: Postpartum exercise program group
The participant will follow a program of postpartum exercises, 30 minutes, 3 sessions / week for 6 weeks. |
The postpartum exercise program will begin with 6-minute warm up stretching exercises for hamstrings, hip adductors, gluteal muscles, quadriceps, calves and soleus. The main phase of exercise program will consist of core stabilization exercises, done for 10 repetition and repeated twice / day, total of 30 minutes, 3 sessions / week for 6 weeks. It will include abdominal breathing exercise, bridge exercises and kneeling abdominal exercises. |
|
Experimental: Low intensity pulsed ultrasound and postpartum exercise program group
The participants will receive low intensity pulsed ultrasound with frequency 0.7-1.0 MHz for 30 minutes, 3 sessions / week for 6 weeks, in addition to the same program of postpartum exercises. |
The postpartum exercise program will begin with 6-minute warm up stretching exercises for hamstrings, hip adductors, gluteal muscles, quadriceps, calves and soleus. The main phase of exercise program will consist of core stabilization exercises, done for 10 repetition and repeated twice / day, total of 30 minutes, 3 sessions / week for 6 weeks. It will include abdominal breathing exercise, bridge exercises and kneeling abdominal exercises. The participants will receive therapeutic ultrasound using the following parameters: frequency 0.7-1 MHz, with intensity <3 W/cm2 for 30 min, 6 hours post vaginal delivery and 24 hours post cesarean section. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Uterine involution
Time Frame: 6 weeks
|
A diagnostic ultrasound device (EDAN, DUS 60, China), with 2.5-MHz convex transducer will be used to trace fundus level and progression of uterine involution before and after the intervention for all participants in both groups. |
6 weeks
|
|
Pain Intensity
Time Frame: 6 weeks
|
Visual analogue scale (VAS) will be used to assess pain intensity. It is a numeric scale, usually represents a horizontal line, 100 mm (10cm) in length, representing the severity of symptoms from 0 "no symptoms" to 10 "very severe symptoms . VAS is a valuable and reliable tool for the documentation of symptom severity, treatment effectiveness. |
6 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Hossam H Kamel, Professor, Al-Azhar University
- Study Chair: Hala M Omara, Professor, Cairo University
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- P.T.REC/012/006454
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.